Concepedia

Joi Dunbar

JD

Statistics

Publications

15

Citations

931

H-Index

12

Active since

1980

Affiliations

Infinity Pharmaceuticals (United States)(Current)

Yale Cancer Center

Sarah Cannon

Alkermes (United States)

Dana-Farber Cancer Institute

Joi Dunbar is an author at Infinity Pharmaceuticals (United States) specializing in pharmacology, medicine, and pharmacotherapy.

ORCID

Top concepts

Publications per year

1980–2024

15

Publications

15

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

David G. Winkler, L. Kerrie, Jonathan P. DiNitto et al. · Chemistry & Biology · 2013 · 250 citations

, , +19

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

Antonio Jimeno, Glen J. Weiss, Wilson H. Miller et al. · Clinical Cancer Research · 2013 · 168 citations · Full text

Single‐ and Multiple‐Dose Pharmacokinetics of Long‐acting Injectable Naltrexone

Joi Dunbar, Ryan Z. Turncliff, Qunming Dong et al. · Alcoholism Clinical and Experimental Research · 2006 · 127 citations

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

Andrew J. Wagner, Rashmi Chugh, Lee S. Rosen et al. · Clinical Cancer Research · 2013 · 83 citations · Full text

Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer

William Oh, Matthew D. Galsky, Walter M. Stadler et al. · Urology · 2011 · 74 citations

, , +7

1–5 of 15